Latest Cardiovascular Disease News

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Cardiex Limited has successfully raised $2.4 million through an institutional placement to boost manufacturing and commercial activities for its CONNEQT Pulse device.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

Cardiex Limited has commenced U.S. deliveries of its CONNEQT Pulse arterial health monitor alongside the launch of its companion CONNEQT App, marking a pivotal expansion into the American digital health market.

Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.